Immucell
ICCCImmuCell Corporation is an animal health biologics company specializing in the development and manufacture of products that improve the health and survivability of neonatal dairy and beef calves.
Earnings
Next report
Date not yet announcedCompetitors
By market cap
By revenue growth
Profile
ImmuCell Corporation is an animal health biologics company specializing in the development and manufacture of products that improve the health and survivability of neonatal dairy and beef calves. The company's core value proposition centers on providing immediate passive immunity against calf scours, a leading cause of pre-weaning mortality, through proprietary antibody-based solutions. By utilizing hyperimmunized bovine colostrum, the company offers a science-based alternative to traditional maternal vaccines and nutritional supplements.
ImmuCell is a premium-priced market leader in the calf-level antibody segment, offering the only USDA-licensed orally delivered scours preventatives with guaranteed antibody doses.
FAQ
- What is Immucell's market cap?
- Immucell (ICCC) has a market capitalization of $92.8M and trades on NASDAQ.
- Who are Immucell's competitors?
- Immucell's key competitors include Elanco Animal Health, Zoetis, Merck & Co., and others. These companies compete in similar markets and product categories.
- Where is Immucell headquartered?
- Immucell is headquartered in United States of America and employs approximately 80 people. It has been publicly traded since 1987.